Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan plus pembrolizumab versus placebo plus pembrolizumab in adjuvant clear cell renal cell carcinoma after nephrectomy
2021-003436-92Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in clear cell renal cell carcinoma (ccRCC) comparing Belzutifan plus pembrolizumab with Placebo plus pembrolizumab (2 arms). Primary endpoint: Disease-free survival. Started Nov 2021; status: active.
02
Drugs
belzutifanpembrolizumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2021-003436-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003436-92.